Great points Sydney. I think your SP target of 3c+ makes sense. The catalyst that may boost the SP to 3c+ is the EOFY annual report in late July, as that will provide investors confirmation that the new CEOs savings and growth strategy are paying off.
In the long-term, I think the SP could reach 10c+, as the average PE ratio for the Australian Healthcare Services sector is currently 28.9. If Jayex can reach an annual profit of $2 million per year and be valued at a PE of 28.9, shares would be worth 10.5c with total SOI at 550 million after the largest shareholder exercises his options, and the shares are awarded to Shine Clinical, plus performance bonuses for the Jayex team.
Overall, Jayex is definitely a long-term hold with 10x potential, and as you mentioned, there is a chance for dividends plus the distribution of Medio shares. I will definitely be holding on tightly and accumulating more when I'm able as long as prices stay at these levels.
